In these platforms, the demyelination process characteristic of multiple sclerosis in humans is recapitulated in mice (cuprizone-induced) or rats (LPC-induced). Our flexible study paradigms allow for multiple behavioral, imaging and biomarker assessments, as well as client-specified dosing programs, providing a comprehensive evaluation of the efficacy of your MS therapy candidates in these models.
Following 6 weeks of cuprizone administration, mice exhibit characteristic behaviors of demylination, including impaired gross and fine motor performance as well as increased anxiety and abnormal contextual fear conditioning response. Behavioral observations are supported by quantifying the extent of the pathology using DTI-MRI and SPECT/CT.
Once cuprizone administration is halted, remyelination is observed. Remyelination has become a target for MS therapeutic development because of its potential to decrease the extent of axonal degeneration.
Focal LPC-induced Demyelination
In this platform, demyelination is induced in defined lesion areas in rats through direct infusion of lysolecithin (LPC). Subsequent destruction of white matter is evaluated and visualized with MRI and lesions co-localized with immunohistochemical analyses for myelin basic protein (MBP).